bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
तुलना करने के लिए मीट्रिक्स | BIAF | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBIAFपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.3x | −3.5x | −0.5x | |
PEG अनुपात | −0.02 | −0.34 | 0.00 | |
क़ीमत/बुक | 0.6x | 5.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.8x | 10.2x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 64.5% | 49.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.5% | 6.3% | अनलॉक करें |